Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IPXL

Impax Laboratories (IPXL) Stock Price, News & Analysis

Impax Laboratories logo

About Impax Laboratories Stock (NASDAQ:IPXL)

Advanced Chart

Key Stats

Today's Range
$17.40
$18.95
50-Day Range
$18.30
$18.30
52-Week Range
$13.05
$25.70
Volume
3.04 million shs
Average Volume
945,265 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Receive IPXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impax Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IPXL Stock News Headlines

Impax Global Environmental Markets Fd;Inv
Impax Large Cap Fund Individual Investor
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Impax International Sust Econ Instl
Impax US Sustainable Economy A
Impax Global Opportunities Institutional
Impax Sustainable Allocation Inv
Impax Sustainable Allocation Instl
See More Headlines

IPXL Stock Analysis - Frequently Asked Questions

Impax Laboratories, Inc. (NASDAQ:IPXL) posted its quarterly earnings data on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.20 by $0.03. The company's revenue for the quarter was down 9.4% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Impax Laboratories investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NovoCure (NVCR), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC) and Summit Midstream Partners (SMLP).

Company Calendar

Last Earnings
11/09/2017
Today
4/25/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:IPXL
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:IPXL) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners